A Phase 2 Study of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer Who Had Received Docetaxel-based Chemotherapy

OBJECTIVE: In this Phase 2 multicenter study the efficacy and safety of oral abiraterone acetate (1000 mg/once daily) plus prednisolone (5 mg/twice daily) was evaluated in metastatic castration-resistant prostate cancer patients from Japan who had previously received docetaxel-based chemotherapy. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Satoh, Takefumi, Uemura, Hiroji, Tanabe, Kazunari, Nishiyama, Tsutomu, Terai, Akito, Yokomizo, Akira, Nakatani, Tatsuya, Imanaka, Keiichiro, Ozono, Seiichiro, Akaza, Hideyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243578/
https://www.ncbi.nlm.nih.gov/pubmed/25425730
http://dx.doi.org/10.1093/jjco/hyu148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243578/
https://www.ncbi.nlm.nih.gov/pubmed/25425730
http://dx.doi.org/10.1093/jjco/hyu148

Ejemplares similares